Holen Sie sich die Stockscreener-App
14.19
0.50%
0.07
Handel nachbörslich:
14.70
0.51
+3.59%
Schlusskurs vom Vortag:
$14.12
Offen:
$14.05
24-Stunden-Volumen:
650.95K
Relative Volume:
0.41
Marktkapitalisierung:
$1.27B
Einnahmen:
$-249.00K
Nettoeinkommen (Verlust:
$-187.60M
KGV:
-5.676
EPS:
-2.5
Netto-Cashflow:
$-201.88M
1W Leistung:
+5.19%
1M Leistung:
+21.80%
6M Leistung:
+263.85%
1J Leistung:
+296.37%
1-Tages-Spanne:
$13.60
$14.25
1-Wochen-Bereich:
$13.17
$15.16
52-Wochen-Spanne:
$2.865
$15.16
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Branche
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.19 | 1.51B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Using flow based indicators on Amylyx Pharmaceuticals Inc.July 2025 Reactions & Weekly Hot Stock Watchlists - newser.com
Using economic indicators to assess Amylyx Pharmaceuticals Inc. potentialJuly 2025 Catalysts & Safe Capital Investment Plans - newser.com
Will Amylyx Pharmaceuticals Inc. stock continue upward momentumMarket Volume Report & Daily Entry Point Trade Alerts - newser.com
Amylyx Pharmaceuticals, Inc. Securities Lawsuit Investigation - Claim Depot
Published on: 2025-10-13 09:41:01 - newser.com
Why Amylyx Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Volume & Daily Growth Stock Tips - newser.com
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, - GlobeNewswire
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidance2025 Volatility Report & Smart Allocation Stock Tips - newser.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9.6%Should You Buy? - MarketBeat
Key metrics from Amylyx Pharmaceuticals Inc.’s quarterly dataWeekly Profit Analysis & Fast Entry Momentum Alerts - newser.com
Will Amylyx Pharmaceuticals Inc. continue its uptrendJuly 2025 Trends & Safe Capital Growth Plans - newser.com
Best data tools to analyze Amylyx Pharmaceuticals Inc. stockJuly 2025 Outlook & Fast Entry and Exit Trade Plans - newser.com
Leerink Partnrs Has Bullish Forecast for AMLX Q3 Earnings - MarketBeat
How supply chain issues affect Amylyx Pharmaceuticals Inc. stockBond Market & Accurate Buy Signal Alerts - newser.com
Could Legal Scrutiny of AMLX’s Disclosures Reshape Management Credibility at Amylyx Pharmaceuticals? - simplywall.st
Institutional scanner results for Amylyx Pharmaceuticals Inc.Weekly Stock Report & High Yield Stock Recommendations - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
MarketsMedicine Hat News - FinancialContent
Amylyx Pharmaceuticals (AMLX): A Fresh Look at Valuation Following New Legal Investigation - Sahm
Amylyx Faced With Big Rally Reality Check: Why I Choose To Hold (NASDAQ:AMLX) - Seeking Alpha
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 4%What's Next? - MarketBeat
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - cnhinews.com
Amylyx Pharmaceuticals prices $175M public offering - MSN
Visual analytics tools that track Amylyx Pharmaceuticals Inc. performanceQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Have Amylyx Pharmaceuticals Insiders Been Selling Stock? - simplywall.st
B of A Securities Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation - Nasdaq
Amylyx drops clinical program for neuro disorder after trial readout - MSN
Amylyx Will Battle Investor Suit Over Revoked ALS Treatment (1) - Bloomberg Law News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Amylyx stock price target raised to $16 from $14 at BofA Securities - Investing.com
BofA Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $16 - 富途牛牛
Strategic Growth and Financial Flexibility Position Amylyx Pharmaceuticals for Success: Buy Rating with $16 Price Target - TipRanks
Amylyx Pharmaceuticals Executives Cash In on Major Stock Sales! - TipRanks
Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Sells $128,712.24 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Camille Bedrosian Sells 12,039 Shares - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CFO Sells $154,674.70 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Justin Klee Sells 29,975 Shares - MarketBeat
Amylyx Pharmaceuticals Inc Stock Analysis and ForecastVolume Spike Alerts & Free Trading Psychology Sessions - earlytimes.in
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Down 6.5%Here's What Happened - MarketBeat
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) - MSN
Amylyx Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):